Skip to main content
main-content

01.12.2012 | Research | Ausgabe 1/2012 Open Access

Health and Quality of Life Outcomes 1/2012

Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire

Zeitschrift:
Health and Quality of Life Outcomes > Ausgabe 1/2012
Autoren:
Esteban Dauden, Enrique Herrera, Lluis Puig, José Luis Sánchez-Carazo, Jaime Toribio, Ma Teresa Caloto, Gonzalo Nocea, Montse Roset, Nuria Lara
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1186/​1477-7525-10-56) contains supplementary material, which is available to authorized users.

Competing interests

Esteban Dauden: Advisory Board member, consultant, grants, research support, participation in clinical trials, honorarium for speaking, research support, with the following pharmaceutical companies: Abbott, Amgen, Astellas, Centocor Ortho Biotech Inc., Galderma, Glaxo, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, Celgene. Enrique Herrera: None declared. Lluis Puig: Has received from Merck honorarium for speaking at meetings, participation on advisory boards and participation in clinical trials. José Luis Sánchez-Carazo: None declared. Jaime Toribio: None declared. Ma. Teresa Caloto: None declared. Gonzalo Nocea: None declared. Montse Roset: None declared. Nuria Lara: None declared.

Abstract

Background

Several questionnaires have been used to measure health related quality of life (HRQoL) in patients with psoriasis, few have been adapted for use in Spain; none of them was developed specifically for the Spanish population. The purpose of the study was to validate and assess the sensitivity to change of a new questionnaire to measure HRQOL in patients with psoriasis (PSO-LIFE).

Methods

Observational, prospective, multicenter study performed in centers around Spain. Patients with active or inactive psoriasis completed the PSO-LIFE together with other Dermatology Quality of Life Index (DLQI) and Psoriasis Disability Index (PDI). A control group of patients with urticaria or atopic dermatitis was also included. Internal consistency and test-retest reliability of the PSO-LIFE were assessed by calculating Cronbach’s alpha and Intraclass Correlation Coefficient (ICC). Validity was assessed by examining factorial structure, the capacity to discriminate between groups, and correlations with other measures. Sensitivity to change was measured using effect sizes.

Results

The final sample included for analysis consisted of 304 patients and 56 controls. Mean (SD) age of psoriasis patients was 45.3 (14.5) years compared to 38.8 (14) years for controls (p < 0.01). Cronbach’s alpha for the PSO-LIFE was 0.95 and test-retest reliability using the ICC was 0.98. Factor analysis showed the questionnaire to be unidimensional. Mean (SD) PSO-LIFE scores differed between patients with psoriasis and controls (64.9 [22.5] vs 69.4 [17.3]; p < 0.05), between those with active and inactive disease (57.4 [20.4] vs 76.4 [20.6]; p < 0.01), and between those with visible and non-visible lesions (63.0 [21.9] vs. 74.8 [23.9]; p < 0.01). The correlation between PSO-LIFE and PASI scores was moderate (r = −0.43) while correlations with DLQI and PDI dimensions ranged from moderate to high (between 0.4 and 0.8). Effect size on the PSO-LIFE in patients reporting ‘much improved’ health status at study completion was 1.01 (large effect size).

Conclusions

The present results provide substantial support for the reliability, validity, and responsiveness of the PSO-LIFE questionnaire in the population for which it was designed.
Zusatzmaterial
Additional file 1: PSO-LIFE Questionnaire. (DOC 30 KB)
12955_2011_967_MOESM1_ESM.doc
Authors’ original file for figure 1
12955_2011_967_MOESM2_ESM.png
Authors’ original file for figure 2
12955_2011_967_MOESM3_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 1/2012

Health and Quality of Life Outcomes 1/2012 Zur Ausgabe